Evaluation of Immunotherapies
Research type
Research Study
Full title
Discovery and evaluation of novel immunotherapies
IRAS ID
300408
Contact name
Krzysztof B. Wicher
Contact email
Sponsor organisation
Macomics Ltd
Duration of Study in the UK
10 years, 0 months, 0 days
Research summary
The main objectives of the study are to develop novel immunotherapies to treat human diseases and to identify potential biomarkers which can be used in the clinic. Clinical indications being addressed include but are not limited to cancer. The use of human tissue is required for laboratory studies to discover novel biological functions, and to ensure the specificity and safety of the immunotherapies generated. Human anonymised samples will be obtained from approved suppliers (commercial suppliers, academic collaborations and Macomics clinical studies) and will encompass fresh, frozen and fixed cells (e.g. from blood) and tissues (e.g. resected tumours and corresponding normal tissues).
REC name
South West - Frenchay Research Ethics Committee
REC reference
21/SW/0173
Date of REC Opinion
2 Dec 2021
REC opinion
Unfavourable Opinion